# Dual Wavelength Spectrophotometric Method for  Simultaneous Estimation of Atorvastatin Calcium and  Felodipine from Tablet Dosage Form

Authors: Namdeo R. Jadhav; Ramesh S. Kambar; Sameer J. Nadaf
Journal: Advances in Chemistry
 (2014)

---

## Abstract

Atorvastatin calcium (ATR) and felodipine (FEL) are beneficial in combination for elderly people in management of hypertension and atherosclerosis. Aim of present study is to develop simple, accurate, and precise method for simultaneous quantitative estimation of ATR and FEL from combined tablet dosage form. Method involves simultaneous equation, using acetonitrile—double distilled water (70 : 30)—common solvent showing absorption maxima at 245 and 268 nm. Calibration curves determination for both drugs has been carried out in 0.1 N HCl, phosphate buffer pH 6.8, and acetonitrile (ACN)—water (70 : 30 V/V).  Linearity range was observed in the concentration range of 2 to 12µg/mL for FEL and 20 to 100 µg/mL for ATR. Percent concentration estimated for ATR and FEL was 100.12 ± 1.03 and 99.98 ± 0.98, respectively. The method was found to be simple, economical, accurate and precise and can be used for quantitative estimation of ATR and FEL.


---

## Body

## 1. Introduction

Atorvastatin (ATR) is chemically described as [R-(R*, R*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid (Figure 1). It is a member of the drug class known as statins, used for lowering blood cholesterol [1]. It also stabilizes plaque and prevents strokes through anti-inflammation and other mechanisms. It inhibits HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. Inhibition of this enzyme stops the reduction of HMG-CoA to mevalonate, which is the rate-limiting step in hepatic cholesterol biosynthesis. Inhibition of the enzyme decreases cholesterol synthesis and ultimately increases expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes [2, 3].Figure 1
Structure of (I) atorvastatin, (II) felodipine.Felodipine (FEL) is a 1, 4 dihydropyridine derivative, that is, chemically described as ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(2,3 dichlorophenyl)-3,5-pyridinedicarboxylate. It is a dihydropyridine calcium channel blocker used mainly for the management of hypertension and angina pectoris like the other calcium channel blockers [4].Literature survey reveals that spectrophotometric and chromatographic methods, and a stability-indicating LC method, have been reported for determination of ATR in pharmaceutical preparations in combination with other drugs [5–13]. Several chromatographic and spectrophotometric methods have been reported for felodipine assay [14–18]. However, most of the analytical methods developed for the quantization of ATR and FEL involve analysis of single component or combination with other drugs. No effective method has been reported for quantitative estimation of ATR and FEL from combined dosage form.


## 2. Material and Methods

Atorvastatin calcium and felodipine were kindly gifted by Cipla Ltd., Goa, India. Acetonitrile (Loba Chemie Pvt. Ltd., Mumbai, India) and other chemicals used are of analytical grade. Distilled water was prepared in laboratory.


### 2.1. Preparation of Bilayered Tablet

Bilayered tablets of total weight of 300 mg each, containing 150 mg immediate release layer of ATR (10 mg API) and 150 mg of sustained release layer of FEL (10 mg API), were prepared by initially adding FEL granules to die of RIMEK minipress (Karnavati engineering, Gujarat, India) and compressed, above which ATR blend was poured and allowed to undergo for the final compression to prepare the bilayered tablet using 8 mm flat faced punches.


### 2.2. Standard Stock Solution

#### 2.2.1. In 0.1 N HCl

Standard stock solution was prepared by dissolving 10 mg of ATR and 10 mg of FEL separately in 100 mL of volumetric flask containing 10 mL of 0.1 N HCl. Then, the final volume of the solution was made up to 100 mL with 0.1 N HCl to get stock solution of 100µg/mL. Adequate quantities were sampled out from the standard stock solution in 10 mL volumetric flask to get concentration of 10, 20, 30, 40, 50, and 60 µg/mL ATR and 2, 4, 6, 8, 10, and 12 µg/mL FEL. Then, the absorbances of the solution was measured at 268 nm (λ max of FEL) and 245 nm (λ max of ATR) using double beam UV visible spectrophotometer against 0.1 N HCl as blank.


#### 2.2.2. In Phosphate Buffer pH 6.8

All the above procedure was repeated using phosphate buffer pH 6.8 instead of 0.1 N HCl. Calibration curve of ATR and FEL in 0.1 N HCl and phosphate buffer (PB) pH 6.8 are shown in Figures2 and 3, respectively. Absorbance values are shown in Table 1.Table 1
Absorbance values for calibration curves of FEL and ATR at 268 and 245 nm.
FEL
ATR
Concentration (μg/mL)
Absorbance
Concentration (μg/mL)
Absorbance
268 nm
245 nm
268 nm
245 nm
20
0.17069
0.05085
2
0.12878
0.02782
40
0.33971
0.10072
4
0.24756
0.05264
60
0.52023
0.15256
6
0.37096
0.08296
80
0.68275
0.21401
8
0.50512
0.11161
100
0.84833
0.25425
10
0.62368
0.13909
—
—
—
12
0.76792
0.16704Figure 2
Calibration curve of ATR in 0.1 N HCl and phosphate buffer (PB) pH 6.8.Figure 3
Calibration curve of FEL in 0.1 N HCl and phosphate buffer (PB) pH 6.8.


### 2.3. UV Method Development and Optimization

#### 2.3.1. Selection of Common Solvent

ACN—double distilled water (70 : 30% V/V)—was selected as common solvent for developing spectral characteristics of drugs. The selection was made after assessing the solubility of both drugs in different solvents.


#### 2.3.2. Preparation of Standard Drug Solution

(
1) ATR Standard Stock Solution (100μg/mL). Accurately weighed quantity of Atorvastatin calcium (10 mg) was transferred into 100 mL volumetric flask dissolved in 60 mL of ACN—water (70 : 30% V/V)—and diluted up to mark with same solvent. This will give a stock solution having strength of 100 μg/mL.(2) FEL Standard Stock Solution (100μg/mL). Accurately weighed quantity of felodipine (10 mg) was transferred into 100 mL volumetric flask dissolved in 60 mL of ACN—water (70 : 30% V/V)—and diluted up to mark with same solvent. This will give a stock solution having strength of 100 μg/mL.


#### 2.3.3. Construction of Calibration Curve

(
1) Calibration Curve for ATR. Different aliquots were withdrawn from the standard stock solution and diluted with appropriate quantity of ACN—water (70 : 30% V/V)—to get a series of concentration ranging from 20 to 100 μg/mL. Absorbance was measured at different concentrations and the calibration curve was prepared by plotting absorbance versus concentration.(2) Calibration Curve for FEL. Different aliquots were withdrawn from the standard stock solution and diluted with appropriate quantity of ACN—water (70 : 30% V/V)—to get a series of concentration ranging from 2 to 12 μg/mL. Absorbance was measured at different concentrations and the calibration curve was prepared by plotting absorbance versus concentration.


#### 2.3.4. Selection of Wavelength

By appropriate dilutions of two standard drug solutions with ACN—double distilled water (70 : 30% V/V)—solutions containing 10μg/mL of ATR and 10 μg/mL of FEL were scanned separately in the range of 200–400 nm to determine the wavelength of maximum absorption for both drugs (Figure 4).UV spectra of (a) ATR, (b) FEL in ACN: water (70 : 30% V/V).
(a)
(b)


#### 2.3.5. Selection of Method and Wavelength

For quantitative estimation of ATR and FEL, simultaneous equation method employing 245 nm and 268 nm as analytical wavelength was used. The two wavelengths were chosen from the overlain spectra of ATR and FEL. Overlain spectra of ATR and FEL are shown in Figure5.Figure 5
Overlain spectra of ATR and FEL.


### 2.4. Procedure for Calculating Absorptivity of Both the Drugs at Selected Wavelengths

From standard drug solutions, six works in standard solutions with concentration of 20, 40, 60, 80, and 100μg/mL for ATR and 2, 4, 6, 8, 10, and 12 μg/mL for FEL were prepared and scanned separately on the selected wavelengths for both the drugs. The absorptivity at selected wavelength was calculated.


### 2.5. Analysis of Tablet Formulation

Twenty tablets were powdered. Tablet formulation containing ATR 10 mg and FEL 10 mg was analyzed using this method. From the triturates of 3 tablets, an amount equivalent to 10 mg of ATR and 10 mg of FEL was weighed and dissolved in 10 mL of ACN—water (70 : 30% V/V)—and sonicated for 10 min. Then, the solution was filtered through Whatman filter paper number 41 and then final volume of the solution was made up to 100 mL with ACN—double distilled water (70 : 30% V/V)—to get a stock solution containing 100μg/mL of ATR and 100 μg/mL FEL.Appropriate aliquots of ATR and FEL within Beer’s law limit were taken and analyzed by the proposed method using the procedure described earlier. The concentration of ATR and FEL present in the sample solution was calculated by using the simultaneous equation,(1)Cy=A1ax2-A2ax1ax2ay1-ax1ay2,Cx=A1ay2-A2ay1ax2ay1-ax1ay2,
where Cy is the concentration of ATR in gm/lit, Cx is the concentration of FEL in gm/lit, A1 is the absorbance of sample solution at 268 nm, A2 is the absorbance of sample solution at 245 nm, ax1 is the absorptivity of FEL at 268 nm, ay1 is the absorptivity of ATR at 268 nm, ax2 is the absorptivity of FEL at 245 nm, and ay2 is the absorptivity of ATR at 245 nm.


### 2.6. Method Validation

#### 2.6.1. Linearity

In quantitative analysis, the calibration curve was constructed for both ATR and FEL after analysis of consecutively increased concentrations.


#### 2.6.2. Recovery Studies

Accuracy of analysis was determined by performing recovery studies by spiking different concentrations of pure drug in the preanalyzed tablet samples within the analytical concentration range of the proposed method at three different sets at levels of 80, 100, and 120%. The added quantities of the individual drugs were estimated by above method. Intraday precision and interday precision have also been carried out.


#### 2.6.3. Interday Precision

Analysis of drug was performed on two different days and the deviation in the results was observed. Results are shown in Table4.


#### 2.6.4. Intraday Precision

Analysis of drug was performed on the same day in morning and evening, and the deviation in the results was observed. Results are shown in Table5.


#### 2.6.5. Ruggedness

Ruggedness of the method was confirmed by the analysis of formulation that was done by the different analysts, using similar operational and environmental conditions.


## 2.1. Preparation of Bilayered Tablet

Bilayered tablets of total weight of 300 mg each, containing 150 mg immediate release layer of ATR (10 mg API) and 150 mg of sustained release layer of FEL (10 mg API), were prepared by initially adding FEL granules to die of RIMEK minipress (Karnavati engineering, Gujarat, India) and compressed, above which ATR blend was poured and allowed to undergo for the final compression to prepare the bilayered tablet using 8 mm flat faced punches.


## 2.2. Standard Stock Solution

### 2.2.1. In 0.1 N HCl

Standard stock solution was prepared by dissolving 10 mg of ATR and 10 mg of FEL separately in 100 mL of volumetric flask containing 10 mL of 0.1 N HCl. Then, the final volume of the solution was made up to 100 mL with 0.1 N HCl to get stock solution of 100µg/mL. Adequate quantities were sampled out from the standard stock solution in 10 mL volumetric flask to get concentration of 10, 20, 30, 40, 50, and 60 µg/mL ATR and 2, 4, 6, 8, 10, and 12 µg/mL FEL. Then, the absorbances of the solution was measured at 268 nm (λ max of FEL) and 245 nm (λ max of ATR) using double beam UV visible spectrophotometer against 0.1 N HCl as blank.


### 2.2.2. In Phosphate Buffer pH 6.8

All the above procedure was repeated using phosphate buffer pH 6.8 instead of 0.1 N HCl. Calibration curve of ATR and FEL in 0.1 N HCl and phosphate buffer (PB) pH 6.8 are shown in Figures2 and 3, respectively. Absorbance values are shown in Table 1.Table 1
Absorbance values for calibration curves of FEL and ATR at 268 and 245 nm.
FEL
ATR
Concentration (μg/mL)
Absorbance
Concentration (μg/mL)
Absorbance
268 nm
245 nm
268 nm
245 nm
20
0.17069
0.05085
2
0.12878
0.02782
40
0.33971
0.10072
4
0.24756
0.05264
60
0.52023
0.15256
6
0.37096
0.08296
80
0.68275
0.21401
8
0.50512
0.11161
100
0.84833
0.25425
10
0.62368
0.13909
—
—
—
12
0.76792
0.16704Figure 2
Calibration curve of ATR in 0.1 N HCl and phosphate buffer (PB) pH 6.8.Figure 3
Calibration curve of FEL in 0.1 N HCl and phosphate buffer (PB) pH 6.8.


## 2.2.1. In 0.1 N HCl

Standard stock solution was prepared by dissolving 10 mg of ATR and 10 mg of FEL separately in 100 mL of volumetric flask containing 10 mL of 0.1 N HCl. Then, the final volume of the solution was made up to 100 mL with 0.1 N HCl to get stock solution of 100µg/mL. Adequate quantities were sampled out from the standard stock solution in 10 mL volumetric flask to get concentration of 10, 20, 30, 40, 50, and 60 µg/mL ATR and 2, 4, 6, 8, 10, and 12 µg/mL FEL. Then, the absorbances of the solution was measured at 268 nm (λ max of FEL) and 245 nm (λ max of ATR) using double beam UV visible spectrophotometer against 0.1 N HCl as blank.


## 2.2.2. In Phosphate Buffer pH 6.8

All the above procedure was repeated using phosphate buffer pH 6.8 instead of 0.1 N HCl. Calibration curve of ATR and FEL in 0.1 N HCl and phosphate buffer (PB) pH 6.8 are shown in Figures2 and 3, respectively. Absorbance values are shown in Table 1.Table 1
Absorbance values for calibration curves of FEL and ATR at 268 and 245 nm.
FEL
ATR
Concentration (μg/mL)
Absorbance
Concentration (μg/mL)
Absorbance
268 nm
245 nm
268 nm
245 nm
20
0.17069
0.05085
2
0.12878
0.02782
40
0.33971
0.10072
4
0.24756
0.05264
60
0.52023
0.15256
6
0.37096
0.08296
80
0.68275
0.21401
8
0.50512
0.11161
100
0.84833
0.25425
10
0.62368
0.13909
—
—
—
12
0.76792
0.16704Figure 2
Calibration curve of ATR in 0.1 N HCl and phosphate buffer (PB) pH 6.8.Figure 3
Calibration curve of FEL in 0.1 N HCl and phosphate buffer (PB) pH 6.8.


## 2.3. UV Method Development and Optimization

### 2.3.1. Selection of Common Solvent

ACN—double distilled water (70 : 30% V/V)—was selected as common solvent for developing spectral characteristics of drugs. The selection was made after assessing the solubility of both drugs in different solvents.


### 2.3.2. Preparation of Standard Drug Solution

(
1) ATR Standard Stock Solution (100μg/mL). Accurately weighed quantity of Atorvastatin calcium (10 mg) was transferred into 100 mL volumetric flask dissolved in 60 mL of ACN—water (70 : 30% V/V)—and diluted up to mark with same solvent. This will give a stock solution having strength of 100 μg/mL.(2) FEL Standard Stock Solution (100μg/mL). Accurately weighed quantity of felodipine (10 mg) was transferred into 100 mL volumetric flask dissolved in 60 mL of ACN—water (70 : 30% V/V)—and diluted up to mark with same solvent. This will give a stock solution having strength of 100 μg/mL.


### 2.3.3. Construction of Calibration Curve

(
1) Calibration Curve for ATR. Different aliquots were withdrawn from the standard stock solution and diluted with appropriate quantity of ACN—water (70 : 30% V/V)—to get a series of concentration ranging from 20 to 100 μg/mL. Absorbance was measured at different concentrations and the calibration curve was prepared by plotting absorbance versus concentration.(2) Calibration Curve for FEL. Different aliquots were withdrawn from the standard stock solution and diluted with appropriate quantity of ACN—water (70 : 30% V/V)—to get a series of concentration ranging from 2 to 12 μg/mL. Absorbance was measured at different concentrations and the calibration curve was prepared by plotting absorbance versus concentration.


### 2.3.4. Selection of Wavelength

By appropriate dilutions of two standard drug solutions with ACN—double distilled water (70 : 30% V/V)—solutions containing 10μg/mL of ATR and 10 μg/mL of FEL were scanned separately in the range of 200–400 nm to determine the wavelength of maximum absorption for both drugs (Figure 4).UV spectra of (a) ATR, (b) FEL in ACN: water (70 : 30% V/V).
(a)
(b)


### 2.3.5. Selection of Method and Wavelength

For quantitative estimation of ATR and FEL, simultaneous equation method employing 245 nm and 268 nm as analytical wavelength was used. The two wavelengths were chosen from the overlain spectra of ATR and FEL. Overlain spectra of ATR and FEL are shown in Figure5.Figure 5
Overlain spectra of ATR and FEL.


## 2.3.1. Selection of Common Solvent

ACN—double distilled water (70 : 30% V/V)—was selected as common solvent for developing spectral characteristics of drugs. The selection was made after assessing the solubility of both drugs in different solvents.


## 2.3.2. Preparation of Standard Drug Solution

(
1) ATR Standard Stock Solution (100μg/mL). Accurately weighed quantity of Atorvastatin calcium (10 mg) was transferred into 100 mL volumetric flask dissolved in 60 mL of ACN—water (70 : 30% V/V)—and diluted up to mark with same solvent. This will give a stock solution having strength of 100 μg/mL.(2) FEL Standard Stock Solution (100μg/mL). Accurately weighed quantity of felodipine (10 mg) was transferred into 100 mL volumetric flask dissolved in 60 mL of ACN—water (70 : 30% V/V)—and diluted up to mark with same solvent. This will give a stock solution having strength of 100 μg/mL.


## 2.3.3. Construction of Calibration Curve

(
1) Calibration Curve for ATR. Different aliquots were withdrawn from the standard stock solution and diluted with appropriate quantity of ACN—water (70 : 30% V/V)—to get a series of concentration ranging from 20 to 100 μg/mL. Absorbance was measured at different concentrations and the calibration curve was prepared by plotting absorbance versus concentration.(2) Calibration Curve for FEL. Different aliquots were withdrawn from the standard stock solution and diluted with appropriate quantity of ACN—water (70 : 30% V/V)—to get a series of concentration ranging from 2 to 12 μg/mL. Absorbance was measured at different concentrations and the calibration curve was prepared by plotting absorbance versus concentration.


## 2.3.4. Selection of Wavelength

By appropriate dilutions of two standard drug solutions with ACN—double distilled water (70 : 30% V/V)—solutions containing 10μg/mL of ATR and 10 μg/mL of FEL were scanned separately in the range of 200–400 nm to determine the wavelength of maximum absorption for both drugs (Figure 4).UV spectra of (a) ATR, (b) FEL in ACN: water (70 : 30% V/V).
(a)
(b)


## 2.3.5. Selection of Method and Wavelength

For quantitative estimation of ATR and FEL, simultaneous equation method employing 245 nm and 268 nm as analytical wavelength was used. The two wavelengths were chosen from the overlain spectra of ATR and FEL. Overlain spectra of ATR and FEL are shown in Figure5.Figure 5
Overlain spectra of ATR and FEL.


## 2.4. Procedure for Calculating Absorptivity of Both the Drugs at Selected Wavelengths

From standard drug solutions, six works in standard solutions with concentration of 20, 40, 60, 80, and 100μg/mL for ATR and 2, 4, 6, 8, 10, and 12 μg/mL for FEL were prepared and scanned separately on the selected wavelengths for both the drugs. The absorptivity at selected wavelength was calculated.


## 2.5. Analysis of Tablet Formulation

Twenty tablets were powdered. Tablet formulation containing ATR 10 mg and FEL 10 mg was analyzed using this method. From the triturates of 3 tablets, an amount equivalent to 10 mg of ATR and 10 mg of FEL was weighed and dissolved in 10 mL of ACN—water (70 : 30% V/V)—and sonicated for 10 min. Then, the solution was filtered through Whatman filter paper number 41 and then final volume of the solution was made up to 100 mL with ACN—double distilled water (70 : 30% V/V)—to get a stock solution containing 100μg/mL of ATR and 100 μg/mL FEL.Appropriate aliquots of ATR and FEL within Beer’s law limit were taken and analyzed by the proposed method using the procedure described earlier. The concentration of ATR and FEL present in the sample solution was calculated by using the simultaneous equation,(1)Cy=A1ax2-A2ax1ax2ay1-ax1ay2,Cx=A1ay2-A2ay1ax2ay1-ax1ay2,
where Cy is the concentration of ATR in gm/lit, Cx is the concentration of FEL in gm/lit, A1 is the absorbance of sample solution at 268 nm, A2 is the absorbance of sample solution at 245 nm, ax1 is the absorptivity of FEL at 268 nm, ay1 is the absorptivity of ATR at 268 nm, ax2 is the absorptivity of FEL at 245 nm, and ay2 is the absorptivity of ATR at 245 nm.


## 2.6. Method Validation

### 2.6.1. Linearity

In quantitative analysis, the calibration curve was constructed for both ATR and FEL after analysis of consecutively increased concentrations.


### 2.6.2. Recovery Studies

Accuracy of analysis was determined by performing recovery studies by spiking different concentrations of pure drug in the preanalyzed tablet samples within the analytical concentration range of the proposed method at three different sets at levels of 80, 100, and 120%. The added quantities of the individual drugs were estimated by above method. Intraday precision and interday precision have also been carried out.


### 2.6.3. Interday Precision

Analysis of drug was performed on two different days and the deviation in the results was observed. Results are shown in Table4.


### 2.6.4. Intraday Precision

Analysis of drug was performed on the same day in morning and evening, and the deviation in the results was observed. Results are shown in Table5.


### 2.6.5. Ruggedness

Ruggedness of the method was confirmed by the analysis of formulation that was done by the different analysts, using similar operational and environmental conditions.


## 2.6.1. Linearity

In quantitative analysis, the calibration curve was constructed for both ATR and FEL after analysis of consecutively increased concentrations.


## 2.6.2. Recovery Studies

Accuracy of analysis was determined by performing recovery studies by spiking different concentrations of pure drug in the preanalyzed tablet samples within the analytical concentration range of the proposed method at three different sets at levels of 80, 100, and 120%. The added quantities of the individual drugs were estimated by above method. Intraday precision and interday precision have also been carried out.


## 2.6.3. Interday Precision

Analysis of drug was performed on two different days and the deviation in the results was observed. Results are shown in Table4.


## 2.6.4. Intraday Precision

Analysis of drug was performed on the same day in morning and evening, and the deviation in the results was observed. Results are shown in Table5.


## 2.6.5. Ruggedness

Ruggedness of the method was confirmed by the analysis of formulation that was done by the different analysts, using similar operational and environmental conditions.


## 3. Result and Discussion

Calibration curve of ATR and FEL was plotted by measuring the absorbance of prepared dilutions of the aforesaid different concentrations at their respective wavelength of maximum absorbance (Figures6 and 7).Figure 6
Calibration curve of ATR in ACN—water (70 : 30 v/v)—at 268 and 245 nm.Figure 7
Calibration curve of FEL in ACN—water (70 : 30 v/v)—at 268 and 245 nm.


### 3.1. Linearity

Linear regression data showed a good linear relationship over a concentration range of 2 to 12µg/mL for FEL and 20 to 100 µg/mL for ATR, whereas, Rajesh et al. demonstrated that linearity was within the range of 2–10 μg/mL for each atorvastatin calcium and felodipine [19]. Six point regression data at both wavelengths (268 nm 245 nm) were generated for FEL (Table 2).Table 2
Absorptivity values for ATR and FEL.
Concentration (μg/mL)
Absorptivity of FEL
Concentration (μg/mL)
Absorptivity of ATR
268 nm
245 nm
268 nm
245 nm
2
0.00603
0.001399
20
0.08533
0.0254
4
0.00618
0.00148
40
0.08539
0.0266
6
0.00638
0.001462
60
0.08548
0.0282
8
0.00654
0.001495
80
0.08562
0.0299
10
0.00673
0.001516
100
0.08586
0.0331
12
0.00698
0.001543
—
—
—
Mean
0.00759
0.001465
Mean
0.08553
0.0286
S.D.
0.44
1.03
S.D.
1.39
0.95


### 3.2. Tablet Analysis

See Table3.Table 3
Results of analysis of laboratory samples.
Label claim (mg/tab)
% concentration estimated*
ATR
100.12 ± 1.03
FEL
99.98 ± 0.98
*Indicates ± SD (n=9).Table 4
Result of recovery studies and interday precision.
Day
Label claim (mg/tablet)
Amount added (%)
Total amount added (mg)
Concentration recovered* (mean ± SD)
% recovery estimated* (mean ± %SD)
Day 1
ATR 10
80
8
8.02 ± 0.34
100.22 ± 1.12
100
10
10.90 ± 0.78
98.10 ± 0.98
120
12
12.23 ± 0.89
103.91 ± 1.23
FEL 10
80
8
8.17 ± 1.45
101.70 ± 1.18
100
10
10.71 ± 1.78
101.68 ± 1.24
120
12
12.99 ± 1.25
99.93 ± 0.98
Day 2
ATR 10
80
8
8.04 ± 1.11
101.11 ± 1.25
100
10
10.08 ± 1.45
101.60 ± 1.17
120
12
12.03 ± 0.34
100.64 ± 1.11
FEL 10
80
8
8.17 ± 1.71
101.70 ± 0.65
100
10
10.22 ± 1.12
97.76 ± 0.34
120
12
12.54 ± 0.34
103.60 ± 0.32
*Indicates ± SD (n=3).Table 5
Result of intraday precision.
Day 1
Label claim (mg/tablet)
Amount added (%)
Total amount added (mg)
Concentration recovered* (mean ± SD)
% recovery estimated* (mean ± %SD)
Morning
ATR 10
80
8
8.04 ± 0.30
100.22 ± 1.12
100
10
10.10 ± 0.34
97.10 ± 0.57
120
12
12.13 ± 0.44
102.79 ± 1.52
FEL 10
80
8
8.27 ± 1.47
101.80 ± 1.74
100
10
10.56 ± 1.78
101.32 ± 1.04
120
12
12.90 ± 1.28
99.99 ± 0.91
Evening
ATR 10
80
8
8.08 ± 1.18
101.64 ± 1.17
100
10
10.04 ± 1.55
101.40 ± 1.87
120
12
12.05 ± 0.28
101.55 ± 1.13
FEL 10
80
8
8.11 ± 1.54
101.28 ± 0.45
100
10
10.14 ± 1.17
99.68 ± 0.56
120
12
12.99 ± 1.98
99.46 ± 0.98
*Indicates ± SD (n=3).


### 3.3. Recovery Study

The added quantities of added drug were estimated by simultaneous equation (Table4).


### 3.4. Interday Precision

Interday precision study was performed and method was found to be precise.


### 3.5. Intraday Precision

Intraday precision study was performed and method was found to be precise. Recoveries obtained for the two drugs do not differ significantly from 100%, which showed that there was no interference from common excipients used in the formulation indicating accuracy and reliability of the method (Table5).


### 3.6. Ruggedness

Ruggedness of the method was tested using different chemical sources of acetonitrile and effects on results were observed and shown in Table6. From the result, it was found that method has ruggedness.Table 6
Ruggedness of the method.
Label claim (mg/tablet)
% recovery estimated* (mean ± %SD)
ATR
FEL
Source I
100/10
102.74 ± 0.35
101.18 ± 0.31
Source II
100/10
103.12 ± 0.35
103.18 ± 0.62
*Indicates ± SD (n=3).


## 3.1. Linearity

Linear regression data showed a good linear relationship over a concentration range of 2 to 12µg/mL for FEL and 20 to 100 µg/mL for ATR, whereas, Rajesh et al. demonstrated that linearity was within the range of 2–10 μg/mL for each atorvastatin calcium and felodipine [19]. Six point regression data at both wavelengths (268 nm 245 nm) were generated for FEL (Table 2).Table 2
Absorptivity values for ATR and FEL.
Concentration (μg/mL)
Absorptivity of FEL
Concentration (μg/mL)
Absorptivity of ATR
268 nm
245 nm
268 nm
245 nm
2
0.00603
0.001399
20
0.08533
0.0254
4
0.00618
0.00148
40
0.08539
0.0266
6
0.00638
0.001462
60
0.08548
0.0282
8
0.00654
0.001495
80
0.08562
0.0299
10
0.00673
0.001516
100
0.08586
0.0331
12
0.00698
0.001543
—
—
—
Mean
0.00759
0.001465
Mean
0.08553
0.0286
S.D.
0.44
1.03
S.D.
1.39
0.95


## 3.2. Tablet Analysis

See Table3.Table 3
Results of analysis of laboratory samples.
Label claim (mg/tab)
% concentration estimated*
ATR
100.12 ± 1.03
FEL
99.98 ± 0.98
*Indicates ± SD (n=9).Table 4
Result of recovery studies and interday precision.
Day
Label claim (mg/tablet)
Amount added (%)
Total amount added (mg)
Concentration recovered* (mean ± SD)
% recovery estimated* (mean ± %SD)
Day 1
ATR 10
80
8
8.02 ± 0.34
100.22 ± 1.12
100
10
10.90 ± 0.78
98.10 ± 0.98
120
12
12.23 ± 0.89
103.91 ± 1.23
FEL 10
80
8
8.17 ± 1.45
101.70 ± 1.18
100
10
10.71 ± 1.78
101.68 ± 1.24
120
12
12.99 ± 1.25
99.93 ± 0.98
Day 2
ATR 10
80
8
8.04 ± 1.11
101.11 ± 1.25
100
10
10.08 ± 1.45
101.60 ± 1.17
120
12
12.03 ± 0.34
100.64 ± 1.11
FEL 10
80
8
8.17 ± 1.71
101.70 ± 0.65
100
10
10.22 ± 1.12
97.76 ± 0.34
120
12
12.54 ± 0.34
103.60 ± 0.32
*Indicates ± SD (n=3).Table 5
Result of intraday precision.
Day 1
Label claim (mg/tablet)
Amount added (%)
Total amount added (mg)
Concentration recovered* (mean ± SD)
% recovery estimated* (mean ± %SD)
Morning
ATR 10
80
8
8.04 ± 0.30
100.22 ± 1.12
100
10
10.10 ± 0.34
97.10 ± 0.57
120
12
12.13 ± 0.44
102.79 ± 1.52
FEL 10
80
8
8.27 ± 1.47
101.80 ± 1.74
100
10
10.56 ± 1.78
101.32 ± 1.04
120
12
12.90 ± 1.28
99.99 ± 0.91
Evening
ATR 10
80
8
8.08 ± 1.18
101.64 ± 1.17
100
10
10.04 ± 1.55
101.40 ± 1.87
120
12
12.05 ± 0.28
101.55 ± 1.13
FEL 10
80
8
8.11 ± 1.54
101.28 ± 0.45
100
10
10.14 ± 1.17
99.68 ± 0.56
120
12
12.99 ± 1.98
99.46 ± 0.98
*Indicates ± SD (n=3).


## 3.3. Recovery Study

The added quantities of added drug were estimated by simultaneous equation (Table4).


## 3.4. Interday Precision

Interday precision study was performed and method was found to be precise.


## 3.5. Intraday Precision

Intraday precision study was performed and method was found to be precise. Recoveries obtained for the two drugs do not differ significantly from 100%, which showed that there was no interference from common excipients used in the formulation indicating accuracy and reliability of the method (Table5).


## 3.6. Ruggedness

Ruggedness of the method was tested using different chemical sources of acetonitrile and effects on results were observed and shown in Table6. From the result, it was found that method has ruggedness.Table 6
Ruggedness of the method.
Label claim (mg/tablet)
% recovery estimated* (mean ± %SD)
ATR
FEL
Source I
100/10
102.74 ± 0.35
101.18 ± 0.31
Source II
100/10
103.12 ± 0.35
103.18 ± 0.62
*Indicates ± SD (n=3).


## 4. Conclusion

In present study, from the observation of the validation parameters, it can be concluded that the developed method is simple, accurate, reliable, and economical for the simultaneous quantitative estimation of atorvastatin calcium and felodipine from combined dosage form using UV spectrophotometric method.



---

*Source: 131974-2014-08-21.xml*